Beyond the Gut: Systemic Metabolic Normalization and Fibrosis Regression Linked to a High-Biodiversity Probiotic—Implications for Radiation-Induced Liver Injury

Liver fibrosis, a progressive accumulation of extracellular matrix proteins, is a common pathological outcome of chronic liver diseases and a significant long-term complication of radiation-induced liver disease (RILD) following oncological radiotherapy. This case report details the notable improvement in an 83-year-old male patient with established liver fibrosis, objectively measured by elastography (FibroScan), who received daily supplementation with a high-biodiversity probiotic (Freeze Dried Bravo probiotic). After approximately six months, the patient's liver stiffness score significantly decreased from 7.6 kPa (moderate fibrosis, F2) to 3.6 kPa (absence of fibrosis, F0). Concurrently, a positive trend towards normalization was observed in several hematochemical parameters, including mean cell hemoglobin concentration (MCHC), blood glucose, serum creatinine, and blood urea nitrogen (BUN), indicating broader metabolic and renal benefits. This striking hepatic improvement is consistent with a prior observation presented in 2013 by one of the authors, involving a severe fibrosis case that regressed with probiotic use. We hypothesize that the unique biodiversity and postbiotic richness of Bravo probiotic, possessing immunomodulatory and detoxifying properties, contributed to these systemic and anti-fibrotic effects by improving gut barrier integrity and reducing inflammation. While acknowledging the limitations of a single case report, these findings suggest a promising non-pharmacological strategy for managing liver fibrosis across various etiologies, including potential applications in mitigating RILD. Further rigorous clinical trials are warranted to validate these observations and elucidate the underlying mechanisms.